Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 in genetic frontotemporal dementia
NL-OMON52800Phase 2Completed
- Sponsor
- Alector
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AL001 in frontotemporal dementia (FTD) (4 arms), sponsored by Alector. Primary endpoints: Adverse events and serious adverse events, Discontinuations due to adverse events and 8 more. Started Nov 2019; status: completed.
02
Drugs
AL001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON52800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52800.